Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Plasma cell 1Gynecologic 1Breast 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Trastuzumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Docetaxel 2zimberelimab 1vactosertib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1saracatinib 1sapanisertib 1relatlimab 1pertuzumab 1pemigatinib 1pembrolizumab 1palbociclib 1osimertinib 1orantinib 1omipalisib 1larotrectinib 1ipatasertib 1fludarabine phosphate 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1cediranib 1capivasertib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × cediranib × Plasma cell × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡